Insider Selling: Dermira, Inc. (DERM) CEO Sells 5,000 Shares of Stock
Dermira, Inc. (NASDAQ:DERM) CEO Thomas G. Wiggans sold 5,000 shares of the company’s stock in a transaction on Tuesday, October 10th. The stock was sold at an average price of $27.52, for a total transaction of $137,600.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Thomas G. Wiggans also recently made the following trade(s):
- On Monday, September 18th, Thomas G. Wiggans sold 9,500 shares of Dermira stock. The stock was sold at an average price of $27.51, for a total transaction of $261,345.00.
- On Tuesday, August 1st, Thomas G. Wiggans sold 500 shares of Dermira stock. The stock was sold at an average price of $27.58, for a total transaction of $13,790.00.
Shares of Dermira, Inc. (DERM) traded down 0.10% during mid-day trading on Wednesday, hitting $28.64. 1,243,357 shares of the stock traded hands. Dermira, Inc. has a 1-year low of $21.35 and a 1-year high of $38.75. The company’s 50-day moving average price is $25.80 and its 200 day moving average price is $28.48. The company’s market capitalization is $1.19 billion.
Dermira (NASDAQ:DERM) last announced its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.89) by ($0.04). The firm had revenue of $1.07 million during the quarter, compared to the consensus estimate of $1.00 million. Dermira had a negative return on equity of 31.66% and a negative net margin of 408.50%. Equities research analysts forecast that Dermira, Inc. will post ($4.20) EPS for the current fiscal year.
Institutional investors have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA boosted its stake in Dermira by 2,220.7% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,154 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 3,975 shares in the last quarter. SG Americas Securities LLC raised its position in Dermira by 66.8% in the 2nd quarter. SG Americas Securities LLC now owns 5,503 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 2,203 shares during the last quarter. KCG Holdings Inc. purchased a new position in Dermira in the 1st quarter worth about $215,000. Legal & General Group Plc raised its position in Dermira by 16.3% in the 1st quarter. Legal & General Group Plc now owns 6,861 shares of the biopharmaceutical company’s stock worth $236,000 after buying an additional 963 shares during the last quarter. Finally, Ardsley Advisory Partners purchased a new position in Dermira in the 2nd quarter worth about $291,000. Institutional investors own 97.56% of the company’s stock.
Several research firms have weighed in on DERM. BidaskClub downgraded shares of Dermira from a “sell” rating to a “strong sell” rating in a report on Thursday, August 10th. Cantor Fitzgerald restated a “buy” rating and set a $45.00 price objective on shares of Dermira in a report on Tuesday, September 26th. Needham & Company LLC restated a “buy” rating and set a $46.00 price objective on shares of Dermira in a report on Sunday, September 17th. Evercore ISI initiated coverage on shares of Dermira in a report on Thursday, June 29th. They issued an “outperform” rating and a $48.00 target price for the company. Finally, Mizuho reiterated a “buy” rating and issued a $43.00 target price (up previously from $40.00) on shares of Dermira in a report on Thursday, September 7th. Four analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $44.40.
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.